Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPER: Adenosine at Different Doses for Myocardial Perfusion
NCT06578234Phase 4Recruiting
- Sponsor
- Region Skåne
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adenosine in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by Region Skåne. Primary endpoint: Myocardial hyperemia. Started Oct 2024; status: recruiting.
02
Drugs
adenosine
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on NCT06578234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06578234.